
Policies
Hypocritical U.S. Patent 6630507 on CBD Contradicts the Known Benefits of Cannabis and the Long-Known History of Medical Marijuana Use
U.S. Patent 6630507 and the Schedule-One contradiction, a tale of hypocrisy.

U.S. Patent 6630507 and the Schedule-One contradiction, a tale of hypocrisy.

By Barbara Venezia Those who believe they’re on the cutting edge of the medical marijuana bubble are passionate, and in some cases, quite controversial. One